Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Fulcrum Therapeutics, Inc. (FULC : NSDQ)
 
 • Company Description   
Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.

Number of Employees: 45

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.85 Daily Weekly Monthly
20 Day Moving Average: 540,379 shares
Shares Outstanding: 53.98 (millions)
Market Capitalization: $423.74 (millions)
Beta: 2.37
52 Week High: $10.13
52 Week Low: $2.32
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 13.77% 10.36%
12 Week 158.22% 123.84%
Year To Date 67.02% 57.79%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
26 LANDSDOWNE STREET
-
CAMBRIDGE,MA 02139
USA
ph: 617-651-8851
fax: -
kgardner@lifesciadvisors.com http://www.fulcrumtx.com
 
 • General Corporate Information   
Officers
Alex C. Sapir - President and Chief Executive Officer
Kate Haviland - Chairman
Alan Musso - Chief Financial Officer
Greg Tourangeau - Vice President
Sonja Banks - Director

Peer Information
Fulcrum Therapeutics, Inc. (CORR.)
Fulcrum Therapeutics, Inc. (RSPI)
Fulcrum Therapeutics, Inc. (CGXP)
Fulcrum Therapeutics, Inc. (BGEN)
Fulcrum Therapeutics, Inc. (GTBP)
Fulcrum Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 359616109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
Share - Related Items
Shares Outstanding: 53.98
Most Recent Split Date: (:1)
Beta: 2.37
Market Capitalization: $423.74 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.18 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 24.66% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/30/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.85
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 34.88%
vs. Previous Quarter: 9.68%
Sales Growth
vs. Year Ago Period: 8,990.91%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -0.20
12/31/24 - -3.94
ROA
06/30/25 - -
03/31/25 - -0.19
12/31/24 - -3.65
Current Ratio
06/30/25 - -
03/31/25 - 28.71
12/31/24 - 22.63
Quick Ratio
06/30/25 - -
03/31/25 - 28.71
12/31/24 - 22.63
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -0.64
12/31/24 - -12.16
Book Value
06/30/25 - -
03/31/25 - 4.23
12/31/24 - 4.51
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©